Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]ONC$377.63-4.64(-1.21%)BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026[4:15:00 AM ET]CMPX$0.77-0.03(-3.97%)Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026[4:15:00 AM ET]CELC$63.20-2.37(-3.61%)Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026[4:15:00 AM ET]ZYME$28.22-0.22(-0.77%)Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026[2:30:00 AM ET]IMTX$7.31-0.23(-3.05%)Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting[2:30:00 AM ET]LLY$1,279.00-27.69(-2.12%)Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug...[2:30:00 AM ET]

XBIT · NASDAQ

XBiotech Inc.

$1.91 -0.04 (-2.28%)

Company overview

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat a variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, as well as a True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$58.2M
Employees
92
Headquarters
Austin, TX
Website
xbiotech.com
CEO
Sushma Shivaswamy
Listed
April 15, 2015
P/E
-1.45
Dividend yield
14.91%

Company financials

Revenue
$0.00
Gross profit
-$332,000
Operating income
-$48.4M
EBITDA
-$39.1M
Net income
-$40.2M
EPS
-$1.32
Total assets
$140M
Total debt
$0.00
Earnings yield
-68.98%

Revenue segmentation

By product (FY 2022)
By region (FY 2022)

No geographic segmentation.

Showing FY 2022

Price chart

1.832.042.262.472.68
XBIT 1D NASDAQ O1.93H1.94L1.86C1.93-0.04 (-2.28%)Vol11.57K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
XBIT Press release XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux GlobeNewswire
XBIT Press release XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers GlobeNewswire
XBIT Press release XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire GlobeNewswire
XBIT Press release XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer GlobeNewswire
XBIT Stock news XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average – What’s Next? Defense World
XBIT Stock news Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB) Defense World
XBIT Stock news Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM) Defense World
XBIT Stock news XBiotech (NASDAQ:XBIT) Share Price Crosses Above Fifty Day Moving Average – Should You Sell? Defense World
See more
FAQ

Questions about XBiotech Inc.

What does XBiotech Inc. do?
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat a variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, as well as a True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
What is XBIT's market cap?
XBiotech Inc. (XBIT) is a listed stock with a live quote. The latest market cap on this page is $58.2M.
Where is XBiotech Inc. headquartered?
XBiotech Inc. is headquartered in Austin, TX.
How do I get XBIT news from the API?
Call GET /v1/news?tickers=XBIT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does XBIT news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for XBIT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the XBIT price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs